AxoGen (AXGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 8. On the o ...

ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may d ...

文章核心观点 - AxoGen公司股价在上一个交易日上涨8.2%,达到8.33美元,成交量较高 [1] - 这一涨幅主要得益于公司上月推出新的神经保护解决方案Avive+ Soft Tissue Matrix,以及预计将在8月发布第二季度财报,第一季度业绩优于预期 [2][3] - 公司预计将在下一季度报告中录得每股亏损0.05美元,同比下降66.7%,但营收将同比增长13.4%至43.27百万美元 [3] - 尽管业绩预期良好,但过去30天内分析师对公司的盈利预测已下调7.3%,这通常不利于股价上涨 [5] 行业概况 - AxoGen属于医疗器械行业,同行业公司Veracyte在上一交易日也上涨4.9%至22.57美元 [7] - 与AxoGen相比,Veracyte最新一季度的每股亏损预期为-0.03美元,同比改善75% [8]

ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. In connection with the commencement of employment on June 17, 2024, and as a material inducement of employment, an award was made under the Company’s Inducement ...

AxoGen (AXGN) recently announced the full launch of its latest product, Avive+ Soft Tissue Matrix. Avive+ is a resorbable, multi-layer amniotic membrane allograft designed for use as a soft tissue barrier. It offers temporary tissue separation and protection during the crucial stage of peripheral nerve recovery.With the introduction of Avive+ Soft Tissue Matrix, Axogen is likely to enhance its comprehensive solutions for nerve protection and address a significant need for patients with compression or non-tr ...

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is proces ...

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is proce ...

AxoGen (AXGN) shares ended the last trading session 5.4% higher at $7.38. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.9% gain over the past four weeks.Axogen scored a strong price increase driven by the optimism surrounding the company’s announcement of opening the Axogen Processing Center (APC) with leaders of the Ohio community on Jun 12, 2024. The new facility in Vandalia will process Axogen’s industry-le ...

ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold indicated for the treatment of peripheral nerve functional deficit and used by surge ...

ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold indicated for the treatment of peripheral nerve functional deficit and used by surg ...